Barclays raised the firm’s price target on Sarepta (SRPT) to $209 from $203 and keeps an Overweight rating on the shares. The company reported a big Q3 beat on both total and Elevidys revenue, the analyst tells investors in a research note. The firm says Sarepta’s reiterated guidance for Elevidys “appeared too conservative.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRPT:
- Sarepta upgraded to Overweight from Neutral at Cantor Fitzgerald
- Sarepta Therapeutics Shows Financial Growth in 2024
- Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
- Sarepta reports Q3 EPS 62c, consensus (13c)
- Notable companies reporting after market close
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
